TG Therapeutics rises on quarterly net product revenue beat

TG Therapeutics

03/03/2025 16:27

** Shares of drugmaker TG Therapeutics TGTX.O rise 15.7% to $34.82

** Co posts Q4 net product revenue of $107.3 million, beating analysts' average estimate of $99.98 million - data compiled by LSEG

** TGTX's Q4 U.S. net product revenue for relapsing multiple sclerosis drug Briumvi came in at $103.6 million

** Co forecasts 2025 total revenue of about $540 million, compared with estimates of $548.2 million

** TGTX rose 71% in the last 12 months

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))